AstraZeneca

AstraZeneca Operating Expenses

Total Operating Expenses of AstraZeneca (AZN) as of Oct 19, 2026.

Operating Expenses

-USD

Last updated:

Total Operating Expenses of AstraZeneca is 2026 - USD. Total Operating Expenses of AstraZeneca was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AstraZeneca Stock analysis

What does AstraZeneca do? AstraZeneca PLC, listed on the stock market with ticker AZN, operates as a biopharmaceutical company focused on prescription medicines. Founded in the UK, it is headquartered in Cambridge, United Kingdom. The company develops, manufactures, and commercializes pharmaceutical products including Imjudo, Tagrisso, Imfinzi, Lynparza, Enhertu, and others. AstraZeneca's products target various therapeutic areas such as oncology, cardiovascular, respiratory, and immunology. The company went public on May 17, 1993. Its website is https://www.astrazeneca.com. AstraZeneca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AstraZeneca stock

On Eulerpool you can find the complete historical development of Total Operating Expenses AstraZeneca since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's AstraZeneca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — AstraZeneca

All Key Metrics — AstraZeneca